These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 15822043)

  • 1. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial.
    Tsujino T; Komatsu Y; Isayama H; Hirano K; Sasahira N; Yamamoto N; Toda N; Ito Y; Nakai Y; Tada M; Matsumura M; Yoshida H; Kawabe T; Shiratori Y; Omata M
    Clin Gastroenterol Hepatol; 2005 Apr; 3(4):376-83. PubMed ID: 15822043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.
    Tsujino T; Isayama H; Nakai Y; Ito Y; Togawa O; Toda N; Arizumi T; Kogure H; Yamamoto K; Mizuno S; Yashima Y; Yagioka H; Sasaki T; Matsubara S; Yamamoto N; Hirano K; Sasahira N; Tada M; Koike K
    J Gastroenterol; 2013 Aug; 48(8):982-8. PubMed ID: 23090004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial.
    Ueki T; Otani K; Kawamoto K; Shimizu A; Fujimura N; Sakaguchi S; Matsui T
    J Gastroenterol; 2007 Feb; 42(2):161-7. PubMed ID: 17351806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial.
    Yoo JW; Ryu JK; Lee SH; Woo SM; Park JK; Yoon WJ; Lee JK; Lee KH; Hwang JH; Kim YT; Yoon YB
    Pancreas; 2008 Nov; 37(4):366-70. PubMed ID: 18953247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial.
    Uchino R; Isayama H; Tsujino T; Sasahira N; Ito Y; Matsubara S; Takahara N; Arizumi T; Toda N; Mohri D; Togawa O; Yagioka H; Yanagihara Y; Nakajima K; Akiyama D; Hamada T; Miyabayashi K; Mizuno S; Kawakubo K; Kogure H; Sasaki T; Yamamoto N; Nakai Y; Hirano K; Tada M; Koike K
    Gastrointest Endosc; 2013 Dec; 78(6):842-850. PubMed ID: 23910063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, randomized, double-blind, placebo-controlled trial of ulinastatin for prevention of hyperenzymemia after double balloon endoscopy via the antegrade approach.
    Itaba S; Nakamura K; Aso A; Tokunaga S; Akiho H; Ihara E; Iboshi Y; Iwasa T; Akahoshi K; Ito T; Takayanagi R
    Dig Endosc; 2013 Jul; 25(4):421-7. PubMed ID: 23368820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study.
    Fujishiro H; Adachi K; Imaoka T; Hashimoto T; Kohge N; Moriyama N; Suetsugu H; Kawashima K; Komazawa Y; Ishimura N; Ishihara S; Amano Y; Kinoshita Y
    J Gastroenterol Hepatol; 2006 Jun; 21(6):1065-9. PubMed ID: 16724996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis.
    Masci E; Cavallini G; Mariani A; Frulloni L; Testoni PA; Curioni S; Tittobello A; Uomo G; Costamagna G; Zambelli S; Macarri G; Innocenti P; Dragonetti C;
    Am J Gastroenterol; 2003 Oct; 98(10):2182-6. PubMed ID: 14572565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproteases in preventing post-ERCP acute pancreatitis.
    Tsujino T; Kawabe T; Omata M
    JOP; 2007 Jul; 8(4 Suppl):509-17. PubMed ID: 17625308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: a prospective, randomized trial.
    Park JY; Jeon TJ; Hwang MW; Sinn DH; Oh TH; Shin WC; Choi WC
    Pancreatology; 2014; 14(4):263-7. PubMed ID: 25062874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial.
    Mansour-Ghanaei F; Joukar F; Taherzadeh Z; Sokhanvar H; Hasandokht T
    World J Gastroenterol; 2016 Jun; 22(21):5114-21. PubMed ID: 27275104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: the Emperor's New Clothes or Aladdin's Magic Lamp?
    Chen S; Shi H; Zou X; Luo H
    Pancreas; 2010 Nov; 39(8):1231-7. PubMed ID: 20531245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trial.
    Fogel EL; Lehman GA; Tarnasky P; Cote GA; Schmidt SE; Waljee AK; Higgins PDR; Watkins JL; Sherman S; Kwon RSY; Elta GH; Easler JJ; Pleskow DK; Scheiman JM; El Hajj II; Guda NM; Gromski MA; McHenry L; Arol S; Korsnes S; Suarez AL; Spitzer R; Miller M; Hofbauer M; Elmunzer BJ;
    Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):132-141. PubMed ID: 31780277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized control study to investigate the application of Ulinastatin-containing contrast medium to prevent post-ERCP pancreatitis.
    Wang J; Su J; Lu Y; Zhou H; Gong B
    Hepatogastroenterology; 2014; 61(136):2391-4. PubMed ID: 25699389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
    Andriulli A; Clemente R; Solmi L; Terruzzi V; Suriani R; Sigillito A; Leandro G; Leo P; De Maio G; Perri F
    Gastrointest Endosc; 2002 Oct; 56(4):488-95. PubMed ID: 12297762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial.
    Poon RT; Yeung C; Liu CL; Lam CM; Yuen WK; Lo CM; Tang A; Fan ST
    Gut; 2003 Dec; 52(12):1768-73. PubMed ID: 14633959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence.
    van Westerloo DJ; Rauws EA; Hommes D; de Vos AF; van der Poll T; Powers BL; Fockens P; Dijkgraaf MG; Bruno MJ
    Gastrointest Endosc; 2008 Aug; 68(2):246-54. PubMed ID: 18455169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
    Cavallini G; Tittobello A; Frulloni L; Masci E; Mariana A; Di Francesco V
    N Engl J Med; 1996 Sep; 335(13):919-23. PubMed ID: 8786777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
    Sherman S; Blaut U; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Earle D; Temkit M; Lehman GA
    Gastrointest Endosc; 2003 Jul; 58(1):23-9. PubMed ID: 12838216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
    Sherman S; Alazmi WM; Lehman GA; Geenen JE; Chuttani R; Kozarek RA; Welch WD; Souza S; Pribble J;
    Gastrointest Endosc; 2009 Mar; 69(3 Pt 1):462-72. PubMed ID: 19231487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.